Erratum to: Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).
Division of Medical Oncology, Department of Hematology-Oncology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
Pere
P
Gascón
Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland.
Matti
M
Aapro
Medizinische Abteilung I-Onkologie und Haematologie, Wilhelminenspital, Wien, Austria.
Heinz
H
Ludwig
Universitaetsklinikum Hamburg Eppendorf, Hamburg, Germany.
Carsten
C
Bokemeyer
Dipartimento di Oncologia e Ematologia, Azienda Ospedaliero, Universitaria S. Giovanni Battista di Torino, Torino, Italy.
Mario
M
Boccadoro
Sandoz Biopharmaceuticals, Holzkirchen, Germany.
Matthew
M
Turner
, Matrix45, Tucson, AZ, USA.
Kris
K
Denhaerynck
, Matrix45, Tucson, AZ, USA.
Karen
K
MacDonald
, Matrix45, Tucson, AZ, USA. abraham@pharmacy.arizona.edu.|Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Drachman Hall B306H, 1295 N Martin, Tucson, AZ, 85721, USA. abraham@pharmacy.arizona.edu.
Ivo
I
Abraham